CINECA IRIS Institutional Research Information System

MASI, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.295
EU - Europa 6.841
AS - Asia 3.346
AF - Africa 276
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 6
Totale 28.787
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.810
IT - Italia 2.696
CN - Cina 1.469
SE - Svezia 1.193
SG - Singapore 946
BG - Bulgaria 749
DE - Germania 536
CA - Canada 480
UA - Ucraina 395
TR - Turchia 388
GB - Regno Unito 316
VN - Vietnam 283
FI - Finlandia 252
CH - Svizzera 209
RU - Federazione Russa 180
CI - Costa d'Avorio 177
HK - Hong Kong 94
FR - Francia 93
IN - India 76
AT - Austria 67
SN - Senegal 46
NG - Nigeria 34
PL - Polonia 34
BE - Belgio 26
NL - Olanda 24
KR - Corea 22
JP - Giappone 18
PK - Pakistan 18
CZ - Repubblica Ceca 16
BJ - Benin 15
ES - Italia 13
AU - Australia 9
LT - Lituania 8
EU - Europa 7
IL - Israele 7
IR - Iran 7
NZ - Nuova Zelanda 6
DK - Danimarca 5
MY - Malesia 5
EG - Egitto 4
PT - Portogallo 4
TW - Taiwan 4
BR - Brasile 3
EE - Estonia 3
GR - Grecia 3
IE - Irlanda 3
LU - Lussemburgo 3
PA - Panama 3
RO - Romania 3
HR - Croazia 2
LV - Lettonia 2
MX - Messico 2
NP - Nepal 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CO - Colombia 1
HU - Ungheria 1
IQ - Iraq 1
KH - Cambogia 1
NO - Norvegia 1
PH - Filippine 1
SM - San Marino 1
Totale 28.787
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.005
Ann Arbor 1.916
Houston 1.476
Fairfield 1.434
Santa Clara 1.262
Chandler 1.205
Milan 1.027
Ashburn 893
Sofia 748
Seattle 662
Jacksonville 595
Cambridge 573
Wilmington 563
New York 516
Singapore 488
Ottawa 458
Boardman 425
Beijing 389
Princeton 311
Lawrence 298
Izmir 278
Medford 266
Nanjing 261
Serra 243
Bern 199
Dearborn 181
Abidjan 177
Pisa 136
Florence 132
Des Moines 125
Dong Ket 110
Shanghai 108
Istanbul 106
Nanchang 106
Rome 106
Jüchen 102
San Diego 92
Hong Kong 84
Redwood City 84
Düsseldorf 79
London 70
Ogden 67
Vienna 67
Los Angeles 61
Kunming 59
Cascina 58
Shenyang 54
Boulder 50
Bremen 49
Dakar 46
Hebei 46
Lancaster 42
Changsha 38
Tianjin 37
Fuzhou 35
Norwalk 35
Lagos 33
Warsaw 33
Hefei 30
Genoa 28
Jiaxing 28
Seacroft 28
Frankfurt am Main 27
Pune 25
Brussels 24
Auburn Hills 23
Guangzhou 23
Hangzhou 23
Kent 22
Orange 21
Lappeenranta 20
Washington 20
Hyderabad 19
Multan 18
Jinan 17
Phoenix 17
Quanzhou 17
Chengdu 15
Cotonou 15
Marseille 15
Munich 15
Helsinki 13
Toronto 13
Detroit 12
Naples 12
Westminster 12
Bologna 11
Turin 11
Vicopisano 11
Castiglione Chiavarese 10
Falls Church 10
San Giuliano Terme 10
Positano 9
Verona 9
Walnut 9
Xian 9
Capannori 8
Center 8
Chicago 8
Dallas 8
Totale 22.782
Salva come PNG Salva come JPEG
Nome #
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 197
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach 186
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 165
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 160
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer 159
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer 158
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 158
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 158
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 157
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group 155
FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis 152
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 151
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine 150
Optimal approach to potentially resectable liver metastases from colorectal cancer 148
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 146
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study 145
Capecitabine (C) in combination with Irinotecan (I) and Oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) 143
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) 143
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? 143
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 143
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) 142
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 142
TAS-102 for the treatment of metastatic colorectal cancer 141
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 140
Palliative treatment of unresectable metastatic colorectal cancer 137
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 137
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 137
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 136
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 135
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 134
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 133
Variations in the Interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer 133
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 133
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 133
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 133
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 132
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 132
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 131
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 131
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 130
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer 129
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 128
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 128
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 128
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 127
null 127
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 124
CETUXIMAB RECHALLENGE IN METASTATIC COLORECTAL CANCER PATIENTS: HOW TO COME AWAY FROM ACQUIRED RESISTENCE? 124
Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI 123
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 122
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 122
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy 121
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 121
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 121
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line folfoxiri 121
Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI 121
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by irinotecan (Ir) + 5-FU/LV (IrFL) followed by docetaxel (T) + 5-FU/LV (TFL) in patients (pts) with metastatic (M) gastric carcinoma (GC): Preliminary results of a phase II trial by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) 120
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 120
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 120
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial 120
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) 119
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 119
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 119
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 119
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 118
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 117
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 117
Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 116
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer 116
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right? 116
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 116
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 115
Oral doxifluridine in advanced hepatocellular carcinoma: a phase II study 115
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 115
Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) 114
Phase III Trial of infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) compared with infusional Fluorouracil,Leucovorin, and Irinotecan (FOLFIRI) as first-line treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest(G.O.N.O.) 114
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 114
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? 114
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 114
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) 113
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable colorectal cancer 113
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target 113
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 113
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 113
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 112
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 112
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 112
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 112
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 112
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts) 111
Optimal strategy to increase the respectability of liver/lung metastases 111
LIVER METASTASES FROM COLORECTAL CANCER: HOW TO BEST COMPLEMENT MEDICAL TREATMENT WITH SURGICAL APPROACHES. 111
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 111
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed 111
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 111
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis 110
Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer 110
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment 109
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment 109
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 109
Totale 12.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.491
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.476 0 0 0 0 0 475 506 312 471 247 382 83
2020/20212.509 219 136 114 107 287 261 182 206 240 178 175 404
2021/20222.900 34 186 93 151 550 470 41 112 117 119 211 816
2022/20233.584 428 365 218 293 456 507 37 271 685 21 264 39
2023/20244.190 521 535 530 324 582 614 285 150 78 85 141 345
2024/20253.023 113 431 167 504 888 920 0 0 0 0 0 0
Totale 29.416